New insider activity at Corcept Therapeutics ( (CORT) ) has taken place on June 18, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Gary Charles Robb, the Chief Business Officer of Corcept Therapeutics, recently executed a sale of 3,185 shares of the company’s stock, amounting to a total transaction value of $225,402.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ strong financial performance and positive earnings outlook drive the stock’s overall score. However, technical indicators and high valuation present cautionary signals. Despite challenges like net income decline and ongoing litigation, the company’s growth potential remains significant.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
YTD Price Performance: 43.79%
Average Trading Volume: 1,686,352
Technical Sentiment Signal: Buy
Current Market Cap: $7.52B
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue